Search Results - "Burris HA 3rd"

Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.

Authors: Burris HA 3rd Jones SF Shipley D et al.

Source: Cancer Investigation. May2010, Vol. 28 Issue 3, p408-412. 5p.

Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.

Authors: Hainsworth JD Spigel DR Burris HA 3rd et al.

Source: Cancer (0008543X). 5/15/2010, Vol. 116 Issue 10, p2448-2454. 7p.

Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.

Authors: Hainsworth JD Spigel DR Burris HA 3rd et al.

Source: Cancer (0008543X). 5/15/2009, Vol. 115 Issue 10, p2138-2146. 9p.

Detection of a point mutation in NQO1 (DT-diaphorase) in a patient with colon cancer.

Authors: Kolesar JM Kuhn JG Burris HA 3rd et al.

Source: JNCI: Journal of the National Cancer Institute. 7/5/95, Vol. 87 Issue 13, p1022-1024. 3p.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors: Baselga J Campone M Piccart M et al.

Source: New England Journal of Medicine. 2/9/2012, Vol. 366 Issue 6, p520-529. 10p.

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.

Authors: Hainsworth JD Infante JR Spigel DR et al.

Source: Cancer (0008543X). 9/1/2010, Vol. 116 Issue 17, p4122-4129. 8p.

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.

Authors: Swanton C Madison RW Tambaoan CFB et al.

Source: Molecular oncology [Mol Oncol] 2025 Nov; Vol. 19 (11), pp. 3060-3078. Date of Electronic Publication: 2025 May 28.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE

Clinical Research in Community Oncology: Advancing Cancer Care Through Localized Clinical Trials.

Authors: Sturgill E Jones C Burris HA 3rd et al.

Source: JCO oncology practice [JCO Oncol Pract] 2026 Jul 01, pp. OP2500922. Date of Electronic Publication: 2026 Jul 01.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101758685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2688-1535 (Electronic) Linking ISSN: 26881527 NLM ISO Abbreviation: JCO Oncol Pract Subsets: MEDLINE

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Authors: Dummer R Sandhu S Miller WH Jr et al.

Source: Future oncology (London, England) [Future Oncol] 2026 Apr; Vol. 22 (9), pp. 995-1013. Date of Electronic Publication: 2026 Mar 31.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE; In Process

Howard A. "Skip" Burris III, MD: an oncology pioneer reflects on patients, progress, and purpose.

Authors: Shaw ML Burris HA 3rd

Source: The American journal of managed care [Am J Manag Care] 2026 Feb; Vol. 32 (Spec. No. 2), pp. SP74-SP76.

Publication Type: Journal Article; Historical Article

Journal Info: Publisher: Clinical Care Targeted Communications Group, LLC Country of Publication: United States NLM ID: 9613960 Publication Model: Print Cited Medium: Internet ISSN: 1936-2692 (Electronic) Linking ISSN: 10880224 NLM ISO Abbreviation: Am J Manag Care Subsets: MEDLINE

The evolving landscape of tissue-agnostic therapies in precision oncology.

Authors: Subbiah V Gouda MA Ryll B et al.

Source: CA: a cancer journal for clinicians [CA Cancer J Clin] 2024 Sep-Oct; Vol. 74 (5), pp. 433-452. Date of Electronic Publication: 2024 May 30.

Publication Type: Journal Article; Review; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0370647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-4863 (Electronic) Linking ISSN: 00079235 NLM ISO Abbreviation: CA Cancer J Clin Subsets: MEDLINE

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.

Authors: Mayer EL Tayob N Ren S et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Feb; Vol. 204 (1), pp. 123-132. Date of Electronic Publication: 2023 Nov 29.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Revolutionizing cancer drug development: Harnessing the potential of basket trials.

Authors: Subbiah V Burris HA 3rd Kurzrock R

Source: Cancer [Cancer] 2024 Jan; Vol. 130 (2), pp. 186-200. Date of Electronic Publication: 2023 Nov 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

Authors: Dummer R Sandhu S Miller WH Jr et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jun 03; Vol. 31 (11), pp. 2097-2107.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.

Authors: Gainor JF Patel MR Weber JS et al.

Source: Cancer discovery [Cancer Discov] 2024 Nov 01; Vol. 14 (11), pp. 2209-2223.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Authors: Oh DY He AR Bouattour M et al.

Source: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2024 Aug; Vol. 9 (8), pp. 694-704. Date of Electronic Publication: 2024 May 29.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Burris HA 3rd Okusaka T Vogel A et al.

Source: The Lancet. Oncology [Lancet Oncol] 2024 May; Vol. 25 (5), pp. 626-635.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Multicenter Study

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

Authors: Burris HA 3rd Moore MJ Andersen J et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Dec 20; Vol. 41 (36), pp. 5482-5492.

Publication Type: Clinical Trial; Research Support, Non-U.S. Gov't; Journal Article

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE; PubMed not MEDLINE

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.

Authors: Yardley DA Liggett W Mainwaring M et al.

Source: Clinical breast cancer [Clin Breast Cancer] 2020 Apr; Vol. 20 (2), pp. 89-97. Date of Electronic Publication: 2019 Jun 26.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.

Authors: Spigel DR Shipley DL Waterhouse DM et al.

Source: The oncologist [Oncologist] 2019 Dec; Vol. 24 (12), pp. e1409-e1416. Date of Electronic Publication: 2019 Aug 16.

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE